Health, Longevity & Biohacking
Mukherjee says GLP-1 add-on cancer trials should be randomised
Peter Attia Drive
412 ‒ The evolving science of cancer: emerging approaches to prevention and early detection, & more
What was said
"I think it's a beautiful study. It would be a beautiful study. You would You would randomize patients with on GLP-1 versus on not GLP-1. You would not GLP-1. You would study their insulinemic response versus their weight loss response."
Siddhartha Mukherjee argues a randomised trial should test standard cancer care against standard care plus a GLP-1 agonist, though he says he does not know of any formal proposal. He suggests focusing on cancers linked to obesity and metabolism and measuring insulin-related effects separately from weight loss; Peter Attia says randomised studies would reduce confounding versus observational data.
Verification status
Attributed speaker claim
Egleze verified who said this and where. The underlying claim has not been independently established by Egleze.
Source and context
Egleze verified who said this and where. The underlying claim has not been independently established by Egleze.
- Speaker
- Siddhartha Mukherjee · guest
- Programme
- Peter Attia Drive
- Episode
- 412 ‒ The evolving science of cancer: emerging approaches to prevention and early detection, & more
- Clip time
- 37:40
- Original source
- Watch the source segment →
From this episode
Peter Attia Drive